Danicopan

AstraZeneca's stock fell 14% in three months due to China subsidiary investigations and sector-wide downturns. Despite challenges, it boasts 12 blockbuster drugs, with oncology leading 40% of revenues. AstraZeneca aims for 25 blockbusters by 2030, focusing on innovation and new technologies, despite recent setbacks and China's VBP impact on Farxiga.

CALQUENCE, a BTK inhibitor, treats MCL and CLL/SLL; serious infections and hemorrhage risk noted. VOYDEYA, a Factor D inhibitor, treats PNH with infection risks. ULTOMIRIS, a C5 inhibitor, treats PNH, aHUS, gMG, and NMOSD with meningococcal infection risk. SOLIRIS, a C5 inhibitor, treats PNH, aHUS, gMG, and NMOSD with meningococcal infection risk.

AstraZeneca presents 57 abstracts at the 66th ASH Annual Meeting, showcasing 13 approved and potential new medicines in haematology, including data on Calquence in CLL and MCL, AZD0486 in lymphomas, and AZD0120 in MM. Alexion highlights Voydeya's efficacy in PNH, and both companies advance understanding of rare haematologic and cardiovascular conditions.

The article content is not provided for summarization.

AstraZeneca (LSE:AZN) reported 18% revenue growth in H1, upgraded full-year guidance, but faces rising costs and net debt. Strengths include strong revenue growth, diverse business model, and pipeline momentum. Weaknesses are high costs, modest operating profit growth, and increased net debt. Opportunities lie in expanding innovative pipeline and emerging markets growth. Threats include intense competition, regulatory challenges, and economic factors.